Aurisco Pharmaceutical, a China-based innovative pharmaceutical CRDMO (contract research, development and manufacturing organisation), announced on Thursday that it has expanded its oligonucleotide manufacturing capacity and a new edition of its corporate website– www.aurisco.com.

The new OligoPilot 2000TM solid-phase synthesiser, from Cytiva, completes Aurisco Biotech's pilot scale cGMP plant and provides immediate capacity availability to accelerate customer's clinical programs, as well as Aurisco's generic oligonucleotide pipeline.

The company said that the new website has been designed to offer a more user-friendly experience with more information, improved navigation and new communication functionalities. It allows visitors to explore the full CRDMO services, product portfolio and advanced technology toolbox and stay informed about the company.

Rafael Antunes, VP Business Development in Europe, said, 'Aurisco has evolved from being a vertically integrated generic API manufacturer with fermentation and synthetic capabilities into a science based CRDMO, offering research, development and cGMP manufacturing of oligonucleotides, RNA conjugates, peptides and complex chiral small molecules. We're working with global organisations, Large Pharma, Biotechs and other CDMOs, Innovators and Generics, and felt the need to evolve our communication channels too. After launching our LinkedIn page last year, we have now launched a revised website, focused on the customer experience.'